Last week, The Telegraph reported that the White House had denied Donald Trump applied for compassionate-use access to retatrutide — an experimental weight-loss drug currently in phase-three clinical trials and not expected to reach FDA approval until at least 2027. The story originated with health news outlet STAT, which reported that a "well connected" 79-year-old had applied for emergency access, had it granted, and that senior health officials had taken notice of the application. The White House hit back fast, calling the reporter an "unserious gossip columnist."
Whether Trump applied or didn't is almost beside the point. The real story is the one underneath it.
The drug and why everyone wants it
Retatrutide — known colloquially as Red Tide or Triple G — is being developed by Eli Lilly, the same company behind Zepbound and Mounjaro. Early trial results have been called a possible "game changer", with weight-loss outcomes described as comparable to bariatric surgery. For context: Ozempic caused a cultural rupture. Retatrutide, if the trial data holds up, would be meaningfully stronger.
The FDA's compassionate use programme exists for exactly this kind of situation — when a patient has a serious or life-threatening condition and no approved treatment options meet their need. The application allegedly sought access to treat "refractory obesity with obstructive sleep apnea and pulmonary hypertension." If that profile is accurate, it's not obviously a frivolous application. Obesity with those comorbidities represents a genuine clinical picture.
But here is the uncomfortable implication of the whole episode: if someone with the resources, connections and political influence of a sitting US president struggled to obtain legitimate access to this drug, what does that say about everyone else who wants it?
When demand outpaces legitimate supply this dramatically, the grey market doesn't fill the gap politely. It fills it with counterfeit vials in unlicensed warehouses.
What happens when supply can't meet demand
I wrote about this in more detail in the context of the broader peptide market in an earlier post, but the retatrutide story is a sharp illustration of a dynamic that's been building for a couple of years now.
Demand for experimental body-optimisation compounds — weight loss, muscle recovery, anti-ageing, cognitive function — is enormous and accelerating. Legitimate supply is constrained by the clinical trial process, prescription requirements and regulatory approval timelines that exist for real reasons. The gap between those two things is where the grey market lives.
The MHRA made their largest-ever single seizure of trafficked weight-loss medicines last October, from a warehouse in Northampton. Much of the haul was labelled as retatrutide. In a separate operation, nearly 2,000 doses were seized from Lincolnshire sites where compounds were being produced without sterile controls or quality assurance. Europol's Operation Shield uncovered networks producing counterfeit peptide drugs in underground labs alongside anabolic steroids.
Eli Lilly — the legitimate maker of retatrutide — has had to run a public awareness campaign on the London Underground warning people not to buy from unregulated sources. Their associate vice-president put it bluntly: "By buying medicine from social media, you are rolling the dice with your health." The company has tested counterfeit versions and found "critical issues" that could cause "significant harm."
All of this exists because the gap is real and the gap is enormous. The Trump story, whether true or not, captures something about that gap that months of enforcement statistics don't quite manage. The most powerful person in the world, with every conceivable resource, apparently couldn't get a straightforward approved route to a drug that clinics are openly advertising as available. So imagine where that pressure lands for everyone else.
The "get results fast" problem
I think about this in the context of what I see in tattooing. The same cultural current that drives grey-market peptide use drives certain corners of the tattoo world too — the hunger for results, for transformation, for a shortcut past the natural timescales that good work requires.
Cheap tattoo shops exist because the gap between what people want to spend and what a quality result actually costs is real. The clients who come to me after a bad experience elsewhere didn't buy a bad tattoo out of stupidity. They bought one because the cheap option was visible and available and the pitch was compelling. The under-the-radar lab producing counterfeit retatrutide is doing the same thing — meeting a genuine demand with a product that looks like the real thing and costs less.
The outcome in both cases is that the people who bear the risk are the buyers. Counterfeit injectables and cheap tattoos both look fine on the day. Both reveal their true quality over time, on your body, in ways that are difficult or impossible to undo.
What this week's story actually changed
Not much, in the immediate term. Retatrutide remains in trials. Approval is still at least a year away. The grey market will continue to operate in the gap. The enforcement operations will continue to find more seized vials.
What the story did — briefly, loudly — was make the demand visible at the very top. There is an enormous appetite for chemical shortcuts to body transformation. That appetite spans every demographic, every income level, every politics. It is being met, unevenly and dangerously, by an unregulated market that profits from the distance between what people want and what regulated medicine currently offers.
That distance is not going to close quickly. The pipeline from clinical trial to approved drug is slow by design — the same design that keeps most of us from injecting untested compounds that turn out to cause harm. The tension between that slowness and the impatience of people who want to change their bodies now is the entire story. It was in April, when the first peptide investigation ran. It was in June, when the Trump story broke. It'll still be there next year.
The only thing that changes in that picture is whether the people navigating it are making decisions with clear information or without it. That's not a regulatory problem. That's just whether the story gets told honestly.